QQQ   427.06 (-0.94%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   427.06 (-0.94%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   427.06 (-0.94%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   427.06 (-0.94%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
NASDAQ:MDXG

MiMedx Group (MDXG) Stock Price, News & Analysis

$6.31
+0.08 (+1.28%)
(As of 12:21 PM ET)
Today's Range
$6.20
$6.31
50-Day Range
$6.23
$8.63
52-Week Range
$3.31
$9.27
Volume
146,168 shs
Average Volume
757,796 shs
Market Capitalization
$927.32 million
P/E Ratio
19.72
Dividend Yield
N/A
Price Target
$12.25

MiMedx Group MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
96.6% Upside
$12.25 Price Target
Short Interest
Healthy
4.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.10mentions of MiMedx Group in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$409,378 Sold Last Quarter
Proj. Earnings Growth
42.42%
From $0.33 to $0.47 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.19 out of 5 stars

Medical Sector

123rd out of 930 stocks

Surgical & Medical Instruments Industry

20th out of 99 stocks

MDXG stock logo

About MiMedx Group Stock (NASDAQ:MDXG)

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

MDXG Stock Price History

MDXG Stock News Headlines

MiMedx Group Inc.
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Northland Securities Keeps Their Buy Rating on MiMedx Group (MDXG)
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
MDXG Apr 2024 7.500 call
MDXG: Another Beat & Raise
MiMedx: Q4 Earnings Snapshot
See More Headlines
Receive MDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/17/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:MDXG
Employees
895
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.25
High Stock Price Target
$14.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+94.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$58.23 million
Pretax Margin
9.53%

Debt

Sales & Book Value

Annual Sales
$321.48 million
Cash Flow
$0.19 per share
Book Value
$0.98 per share

Miscellaneous

Free Float
117,713,000
Market Cap
$927.32 million
Optionable
Optionable
Beta
1.32
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. William F. Hulse IV (Age 50)
    General Counsel & Chief Administrative Officer
    Comp: $677.36k
  • Dr. Robert Benjamin Stein M.D. (Age 73)
    Ph.D., President of Regenerative Medicine & Biologics Innovation
    Comp: $639.28k
  • Mr. Joseph H. Capper (Age 60)
    CEO & Director
  • Mr. Douglas C. Rice CPA (Age 58)
    Chief Financial Officer
  • Mr. Scott M. Turner (Age 58)
    Senior Vice President of Operations & Procurement
    Comp: $493.98k
  • Mr. Matthew M. Notarianni
    Head of Investor Relations
  • Mr. Mark P. Graves (Age 58)
    Senior VP & Chief Compliance Officer
  • Hilary Dixon
    Vice President of Investor Relations & Corporate Strategic Communications
  • Ms. Kate Surdez
    Chief Human Resources Officer
  • Dr. David H. Mason Jr. (Age 77)
    Chief Medical Officer

MDXG Stock Analysis - Frequently Asked Questions

Should I buy or sell MiMedx Group stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDXG shares.
View MDXG analyst ratings
or view top-rated stocks.

What is MiMedx Group's stock price target for 2024?

4 brokers have issued 1-year target prices for MiMedx Group's shares. Their MDXG share price targets range from $11.00 to $14.00. On average, they anticipate the company's stock price to reach $12.25 in the next year. This suggests a possible upside of 96.6% from the stock's current price.
View analysts price targets for MDXG
or view top-rated stocks among Wall Street analysts.

How have MDXG shares performed in 2024?

MiMedx Group's stock was trading at $8.77 on January 1st, 2024. Since then, MDXG stock has decreased by 29.0% and is now trading at $6.23.
View the best growth stocks for 2024 here
.

When is MiMedx Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our MDXG earnings forecast
.

How were MiMedx Group's earnings last quarter?

MiMedx Group, Inc. (NASDAQ:MDXG) announced its earnings results on Wednesday, February, 28th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.08 by $0.04. The company earned $86.83 million during the quarter, compared to the consensus estimate of $85.58 million. MiMedx Group had a net margin of 14.49% and a trailing twelve-month return on equity of 41.12%.

Who are MiMedx Group's major shareholders?

MiMedx Group's stock is owned by many different retail and institutional investors. Top institutional investors include Register Financial Advisors LLC (0.02%). Insiders that own company stock include Mark Graves, Peter M Carlson, Ricci S Whitlow, Rice Doug, Robert Benjamin Stein, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan.
View institutional ownership trends
.

How do I buy shares of MiMedx Group?

Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MDXG) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners